Jan 6 2014
Tauriga Sciences, Inc. or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has a received a comprehensive update from Immunovative Therapies Ltd. ("ITL") highlighting some potentially positive developments.
On January 02, 2014, the Company was notified that ITL will relaunch clinical trials in Thailand (metastatic cancer) and Israel (liver cancer) later this month. Additionally ITL has definitive plans to launch a pivotal Phase II/III trial (breast cancer) during April-May, 2014.
ITL has also launched a new website (http://www.immunocare.net) which has been established to educate patients on the upcoming Allovax trial(s).
Lastly ITL also expects to discuss a new clinical trial for HIV/AIDS, which should be updated shortly on the above-mentioned website.
Tauriga's CEO Seth M. Shaw, expressed, "The Company was very pleased to receive this positive update from ITL, especially concerning the expected launch of the pivotal phase II/III breast cancer trial later in 2014. During 2012, Tauriga made a significant equity investment into ITL and is hopeful for a successful outcome to these clinical trials and ultimately that ITL's technology can be commercialized. The Company will continue to update shareholders when and if receives additional material updates from ITL."
Tauriga Sciences Inc. currently owns 3,280,000 shares of ITL which was the result of an aggregate approximate equity investment of $3,700,000 USD (all investment occurred during calendar year 2012).
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at (www.tauriga.com).
About Pilus Energy LLC
A developer of alternative cleantech energy solutions, Pilus Energy is developing microbial solutions that clean polluting molecules from wastewater. In the process, the technology generates electricity and produces economically important gases and chemicals. Pilus Energy licenses a low-cost, scalable electrogenic bioreactor platform and wastewater-to-value BactoBots. Pilus Energy will also derive additional revenues from carbon and renewable energy credits (REC). For more information, please visit Pilus Energy's web site, (www.pilusenergy.com).
Source: http://taurigasciences.com/